Nirav Niranjan Shah, MD, MS Medical College of Wisconsin 5Live #ASCO20
4:51
Key Insights on Epcoritamab (GEN3013; DuoBody-CD3×CD20) to induce complete response in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL): Complete dose escalation data and efficacy results from a phase I/II trial.
Key Insights on Epcoritamab (GEN3013; DuoBody-CD3×CD20) to induce complete response in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL): Complete dose escalation data and efficacy results from a phase I/II trial.
Non-Hodgkin Lymphoma Similar Videos
-
Loretta Nastoupil, MD; The University of Texas MD Anderson Cancer Center; 5Live #ASH21
6:24
Key insights from the 2021 Annual Hematology meeting in Atlanta
-
Risk stratification and therapy for high-grade NHL_Kristie Blum, MD; #DDHO2021
2:27
-
Matthew Lunning, DO, FACP; University of Nebraska Medical Center; 5Live #ASH21
4:55
Key insights from the 2021 Annual Hematology meeting in Atlanta